Aakaar Medical Technologies IPO is set to open for subscription on June 20, 2025, and will close on June 24, 2025. This is a Book Build Issue through which the company aims to raise approximately ₹27 crores. The IPO consists of a fresh issue of ₹27 crores, while the offer for sale component includes up to [.] equity shares with a face value of ₹10 each.
The Aakaar Medical Technologies IPO price band has been set at ₹68 to ₹72 per share. The retail investor quota is 35%, QIB (Qualified Institutional Buyers) is allotted 50%, and HNI (High Net-Worth Individuals) have a 15% allocation. The listing of shares is expected on the NSE on June 27, 2025, and the IPO allotment date is June 25, 2025.
As per the company’s financials, Aakaar Medical Technologies reported a revenue of ₹61.76 crores in FY 2025, up from ₹46.27 crores in FY 2024. The net profit increased to ₹6.04 crores in FY 2025 from ₹2.87 crores in FY 2024, showcasing a strong financial performance.
Aakaar Medical Technologies IPO Date & Price Band Details
| Category | Details |
|---|---|
| IPO Open Date: | June 20, 2025 |
| IPO Close Date: | June 24, 2025 |
| Face Value: | ₹10 Per Equity Share |
| IPO Price Band: | ₹68 to ₹72 Per Share |
| Issue Size: | Approx ₹27 Crores |
| Fresh Issue: | Approx ₹27 Crores |
| Issue Type: | Book Build Issue |
| IPO Listing: | NSE SME |
| Retail Quota: | Not more than 35% |
| QIB Quota: | Not more than 50% |
| NII Quota: | Not more than 15% |
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
| Anchor Investors List: | Click Here |
Aakaar Medical Technologies Company Overview, Strengths, and Risks
Aakaar Medical Technologies Limited is an Indian aesthetic medical company that offers a diverse selection of specialized cosmetic products and devices. Incorporated in June 2013 (though some sources mention 1999 or 2000 as the establishment year for Aakaar Medical Technologies Private Limited, the public company was incorporated in 2013), the company primarily deals with dermatologists, plastic surgeons, aesthetic physicians, and cosmetologists through a B2B distribution model.
Their product portfolio includes both domestically manufactured products under their own brands and imported devices and products from countries like South Korea, Spain, Italy, and Austria. They offer a wide range of products for homecare and professional skincare, injectables and contouring, hair care, medifacial kits, and advanced medical aesthetic devices like those for tattoo removal, pigmentation, skin rejuvenation, laser hair reduction, and hair transplant.
Aakaar Medical Technologies has a pan-India presence with branches and a team of 90 trained sales and service engineers, serving customers across multiple states including Delhi, Haryana, Punjab, Chandigarh, Uttarakhand, Uttar Pradesh, Bihar, West Bengal, Assam, Gujarat, Madhya Pradesh, Maharashtra, Karnataka, Telangana, and Tamil Nadu.
Company Overview (Financials as of March 31, 2025, from recent IPO filings):
- Revenue: ₹61.76 crores
- Profit After Tax (PAT): ₹6.04 crores
- Total Assets: ₹51.85 crores
- Net Worth: ₹23.20 crores
- Total Borrowing: ₹22.74 crores
- Market Cap: Approximately ₹102 Cr (as of a recent IPO update)
The company recently launched an SME IPO (June 20-24, 2025) to raise capital primarily for working capital requirements and general corporate purposes.
Strengths of Aakaar Medical Technologies:
- Experienced Management & Leadership Team: The company is led by an experienced team, including Dilip Ramesh Meswani, who has over 25 years of industry expertise.
- Diversified Product Base: Aakaar Medical Technologies offers a comprehensive portfolio of aesthetic products and devices (over 150 SKUs) for various needs, from skincare and hair care to injectables and advanced medical devices, making them a “one-stop destination” for aesthetic practitioners.
- Diversified Customer Base: The company serves a large and growing customer base of doctors and clinic chains across India, with a low dependency on any single client (top 10 customers contributed only 10.96% of revenue in FY24).
- Pan-India Reach: They have a strong distribution network and presence across 15 Indian states, supported by a dedicated sales and service team and a partnership with a consignment sales partner (Parekh Integrated Services Pvt. Ltd.) with 21 warehousing centers.
- Strong Financial Growth: The company has shown consistent growth in revenue and profit. Revenue increased by 33% and PAT surged by 110% between FY24 and FY25. They also have good return on equity (ROE) and return on capital employed (ROCE) track records.
- Niche & Growing Market: They operate in the aesthetic medical segment, which is experiencing rapid growth in India due to changing lifestyles, higher disposable incomes, increased awareness, and evolving beauty trends.
Risks of Aakaar Medical Technologies:
- Heavy Reliance on Imported Brands: A significant portion of their product portfolio consists of imported brands. This exposes the company to risks associated with international trade, currency fluctuations, import regulations, and supply chain disruptions.
- Dependence on Third-Party Manufacturers: The company relies on third-party contract manufacturers (domestic and international) and loan licensing partners for manufacturing products. Any issues with these manufacturers could impact their business, operations, and financial condition.
- Geographic Concentration: While they have a pan-India presence, a significant portion of their revenue is derived from specific states like Maharashtra and Karnataka, making them vulnerable to regional economic or regulatory changes.
- Dependency on Third-Party Agent for Storage and Distribution: Their reliance on Parekh Integrated Services Pvt. Ltd. (PISPL) as a consignment sales partner for storage and distribution means any non-performance or breach of their agreement could adversely affect operations.
- Intense Market Competition: The aesthetic and cosmetic medical segment in India is highly competitive, with both domestic and international brands vying for market share. This could lead to pricing pressures and impact profitability.
- Dependency on Specific Professionals: The company’s revenues are largely dependent on demand from dermatologists, aesthetic physicians, and plastic surgeons. A decline in demand from this segment could pose a risk.
- Sudden Boost in Financials (Pre-IPO Year): Some analysts have noted a significant boost in top and bottom lines in FY25 (the pre-IPO year), raising questions about the sustainability of this growth going forward.
- SME Listing Volatility: As the company is listed on the NSE SME platform, its shares may experience higher price volatility and liquidity constraints compared to mainboard listings.
- High Debtor Days: The company has high debtor days (around 166 days as of Mar 2025), which indicates a longer time to collect payments from customers and can impact cash flow.
Aakaar Medical Technologies IPO Market Lot
The Aakaar Medical Technologies IPO has a minimum lot size of 1,600 shares, requiring a minimum investment of ₹1,15,200.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 1600 | ₹1,15,200 |
| Retail Maximum | 1 | 1600 | ₹1,15,200 |
| S-HNI Minimum | 2 | 3200 | ₹2,30,400 |
Aakaar Medical Technologies IPO Allotment & Listing Dates
The Aakaar Medical Technologies IPO will open on June 20, 2025, and close on June 24, 2025. The IPO allotment date is set for June 25, 2025, and the listing on NSE is scheduled for June 27, 2025, marking key dates for investors to track.
| Type | Date |
|---|---|
| IPO Open Date: | June 20, 2025 |
| IPO Close Date: | June 24, 2025 |
| Basis of Allotment: | June 25, 2025 |
| Refunds: | June 26, 2025 |
| Credit to Demat Account: | June 26, 2025 |
| IPO Listing Date: | June 27, 2025 |
Aakaar Medical Technologies IPO: Promoters
The promoters of Aakaar Medical Technologies are Dilip Ramesh Meswani and Bindi Dilip Meswani, who play a key role in driving the company’s vision and growth. Their leadership and industry experience are central to the company’s strategic direction and overall performance in the healthcare technology sector.
Aakaar Medical Technologies IPO Company Financial Report
Aakaar Medical Technologies reported a revenue of ₹61.76 crores in FY 2025, a significant rise from ₹46.27 crores in FY 2024. The company also posted a strong growth in profitability, with net profit increasing to ₹6.04 crores in 2025 compared to ₹2.87 crores in 2024, reflecting robust financial performance.
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax | Assets |
|---|---|---|---|---|
| 2023 | ₹32.88 | ₹29.78 | ₹2.15 | ₹23.23 |
| 2024 | ₹46.27 | ₹42.39 | ₹2.87 | ₹34.01 |
| 2025 | ₹61.76 | ₹53.68 | ₹6.04 | ₹51.85 |
Aakaar Medical Technologies IPO Valuation – FY2025
| KPI | Values |
|---|---|
| ROE: | 33.81% |
| ROCE: | 21.02% |
| EBITDA Margin: | 15.81% |
| PAT Margin: | 9.81% |
| Debt to equity ratio: | 0.98 |
| Earning Per Share (EPS): | ₹6.13 (Basic) |
| Price/Earning P/E Ratio: | 11.74 |
| Return on Net Worth (RoNW): | 33.81% |
| Net Asset Value (NAV): | ₹22.26 |
Aakaar Medical Technologies Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
|---|---|---|---|---|---|
| NA | – | – | – | – | – Cr. |
Objects of the Issue – Aakaar Medical Technologies IPO
The net proceeds from the Aakaar Medical Technologies IPO will be utilized for the following purposes:
- Funding working capital requirements of the company
- General corporate purposes
Aakaar Medical Technologies IPO Review
- Canara Bank
- DRChoksey FinServ
- Emkay Global
- Hem Securities
- IDBI Capital
- Marwadi Shares
- Nirmal Bang
- SBICAP Securities
- Sharekhan
- SMC Global
- Sushil Finance
- Swastika Investmart
- Ventura Securities
- Geojit
- Reliance Securities
- Capital Market
- BP Wealth
- ICICIdirect
- Choice Broking
Aakaar Medical Technologies IPO Registrar
Bigshare Services Pvt Ltd
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/IPO_Status.html
Aakaar Medical Technologies IPO Lead Managers aka Merchant Bankers
- Indorient Financial Services Ltd
Aakaar Medical Technologies Company Address
Aakaar Medical Technologies Limited
801, Heritage Plaza,
Telli Galli Cross Road
Andheri (East),
Mumbai, Maharashtra, 400069
Phone: +91 84528 44024
Email: companysecretary@aakaarmedical.in
Website: https://aakaarmedical.in/
FAQs on Aakaar Medical Technologies IPO
The Aakaar Medical Technologies IPO opens on June 20, 2025, and closes on June 24, 2025.
The IPO price band is set at ₹68 to ₹72 per share.
The minimum lot size is 1,600 shares, requiring a minimum investment of ₹1,15,200.
The IPO allotment date is June 25, 2025, and the listing is scheduled for June 27, 2025 on the NSE SME platform.
The proceeds will be used for funding working capital requirements and for general corporate purposes.
The company is promoted by Dilip Ramesh Meswani and Bindi Dilip Meswani.
Aakaar Medical Technologies reported revenue of ₹61.76 crores and a net profit of ₹6.04 crores in FY 2025.
The IPO will be listed on the NSE SME platform.
Each equity share has a face value of ₹10.
The registrar is Bigshare Services Pvt Ltd.
